Natalia Zhukova

Natalia Zhukova

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KOKristina Orlova
Kristina Orlova
ELEvgeniy V. Ledin
Evgeniy V. Ledin
NZNatalia Zhukova
Natalia Zhukova
RORashida V. Orlova
Rashida V. Orlova
EKElena V. Karabina
Elena V. Karabina
LDLev V. Demidov
Lev V. Demidov
Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.

1 January 2021 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
AMAnna Malkova
Anna Malkova
Vladimir SharoykoVladimir Sharoyko
Vladimir Sharoyko
NZNatalia Zhukova
Natalia Zhukova
AGAnna Gubal
Anna Gubal
ROR.V. Orlova
R.V. Orlova
The modern checkpoint inhibitors block the programmed death-1 receptor and its ligand, cytotoxic T-lymphocyte-associated antigen 4 on tumor cells and lymphocytes, that induces cytotoxic reactions. Nowadays, there are no approved clinical and laboratory predictor markers of immune therapy efficacy, which would allow a more personalized approach to patient selection and treatment. The aim of this review is to analyze possible biomarkers of efficacy for treatment with checkpoint inhibitors according to the pathogenic mechanisms of drug action. The review revealed possible predictive biomarkers, that could be classified to 3 groups: biomarkers of high mutagenic potential of the tumor, biomarkers of high activity of adaptive immunity, biomarkers of low activity of the tumor microenvironment. The determination of the described markers before the start of therapy can be used to formulate a treatment regimen, in which the use of various immunomodulatory drugs, inhibitors of proinflammatory cytokines, angiogenic molecules, and probiotics can be considered.

8 June 2018 in Research and Practical Medicine Journal
Verified
Journal Article
Open access
PDF file
NZNatalia Zhukova
Natalia Zhukova
ROR. V. Orlova
R. V. Orlova
NAN. Yu. Antimonik
N. Yu. Antimonik
SKS. I. Kutukova
S. I. Kutukova
NBN. P. Belyak
N. P. Belyak
SES. P. Erdniev
S. P. Erdniev
The incidence and mortality of skin melanoma in the world and in Russia is growing every year. It should be noted that the proportion of patients with melanoma of late stages remains high. Until recently, only ineffective chemotherapy regimens were available for such patients. That is why the possibility of using modern drugs in real clinical practice for the treatment of this cohort of patients is an urgent issue of modern clinical oncology. The appearance in a real clinical practice of a new group of immunological drugs (anti-CTLA4 and anti-PD-1) for the treatment of patients with metastatic melanoma allows to increase both the time to progression and the life span of this cohort of patients.In this article, we present the experience of St. Petersburg Regional Clinical Hospital “City Clinical Oncology Clinic” in the treatment of patients with metastatic melanoma under the conditions of real clinical practice with the preparation of ipilimumab as part of the expanded access program from February 2014 to March 2017. In total, 31 patients with disseminated melanoma (12 men and 19 women) were treated with ipilimumab during this period. The average age was 57 years (from 39 to 81 years), in 8 patients there were metastases to the brain. Patients with ECOG status 1 at the time of initiation of treatment were the majority 28 patients (90%), three patients (10%) had ECOG status 2. All patients had previously received 1 to 4 lines of systemic chemotherapy. The median of the observation period is currently 12 (3-35) months. The median time to progression was 6 months. At 5 of 31 patients at the time of analysis, signs of progression were not identified. The median overall survival (OB) was 12 months 9 of 31 patients were alive at the time of the analysis. The annual OM was 56.5%, the 2-year period was 29.4%.The article presents a clinical case of treatment of a patient with metastatic melanoma, which will have an effect against the progression of the disease after four lines of therapy, including ipilimumab. The patient was included in the program of expanded access to the PD-1 inhibitor, nivolumab. In all, the patient received 65 nivolumab injections. The life expectancy of the patient from the moment of diagnosing the metastatic stage of the disease is 3.5 years, while 2.5 years on the background of nivolumab therapy. Patient monitoring continues.

7 August 2021 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
ROR. V. Orlova
R. V. Orlova
EKE. A. Kaledina
E. A. Kaledina
AMAnna Malkova
Anna Malkova
NZNatalia Zhukova
Natalia Zhukova
PNP. A. Naymushina
P. A. Naymushina
ATA. V. Tarasov
A. V. Tarasov
The COVID-19 pandemic has affected all medical fields and brought up a lot of serious problems. The features of the COVID-19 infection in patients with cancer are important to understand. According to many articles, patients with cancer are more vulnerable to COVID-19 infection. Patients undergoing anticancer treatment have 1-4% morbidity rate. Patients with hematological diseases and lung cancer are at higher risk of SARS-CoV-2 infection and also have more severe symptoms and complications. In this article we discuss the effect of the tumors on the immune system and comprehend the pathogenesis of the coronavirus disease according to its impact on the immunity. Moreover, in the review we analyze available data about the influence of the different types of cancer therapy (chemotherapy, target therapy, radiotherapy and immunotherapy) on the severity of the COVID-19 infection. Evidence on the effect of chemotherapy on severity and mortality from COVID-19 is contradictory. Whereas there are some authors concluding that chemotherapy treatment is not affecting the severity of COVID-19 disease, there are also some works where the connection between these facts was established. At the same time target therapy, radio- and immunotherapy most likely do not worsen the SARS-CoV-2 infection and are not associated with the development of complications. But it’s important to say that the amount of data available for today is insufficient to make a unambiguous conclusion.

22 January 2026 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Closed access
SZS. К. Zyryanov
S. К. Zyryanov
NZNatalia Zhukova
Natalia Zhukova
Objective: To conduct a cost-effectiveness analysis of first-line treatment regimens based on nurulimab + prolgolimab combination in comparison with ipilimumab + nivolumab combination among adult patients in the Russian Federation with unresectable or metastatic cutaneous melanoma (CM). Material and methods. An adjusted indirect comparison of the efficacy of nurulimab + prolgolimab combination and ipilimumab + nivolumab combination in both dose regimens was conducted according to data from BCD-217-2/OCTAVA and CheckMate 511 randomized controlled trials, respectively. Only direct medical costs for the first-line immunotherapy of unresectable or metastatic CM were taken into account, i.e. manufacture prices with 10% value-added tax and 5% discount rate. The cost-effectiveness analysis was based on estimation of cost per life years gained (LYG) and patient life preservation for a period from 1 to 5 years. Sensitivity analysis was used to assess the impact of price fluctuations on the study results. Results. The total direct costs over 5-year horizon for the nurulimab + prolgolimab combination were 19% lower than that for the ipilimumab 3 mg/kg + nivolumab 1 mg/kg combination, and nurulimab + prolgolimab costs were comparable with the ipilimumab 1 mg/kg + nivolumab 3 mg/kg combination. At the same time, the cost per 1 LYG for the nurulimab + prolgolimab combination therapy turned out to be minimal, amounting to 3.07 million rubles versus 3.44–4.21 million rubles for ipilimumab + nivolumab combinations. In addition, cost per patient life preservation for the nurulimab + prolgolimab combination was lower than that for the ipilimumab 3 mg/kg + nivolumab 1 mg/kg therapy in the first year by 0.7 million rubles (10%), with this difference amounting to 9.1 million rubles (49%) by the fifth year. In comparison with the combination of nurulimab + prolgolimab, the costs for the ipilimumab 1 mg/kg + nivolumab 3 mg/kg combination required to reach patient life preservation in the first year was lower by 1.5 million rubles (20%), although increasing by 4.1 million rubles (23%) vs nurulimab + prolgolimab costs by the fifth year of therapy. Conclusion. Widespread introduction of the nurulimab + prolgolimab combination for unresectable or metastatic CM into current clinical practice will increase patient survival and will contribute to achieving the target indicators of the Russian Ministry of Health in terms of reducing one-year mortality and increasing the proportion of patients with malignant neoplasms registered for 5 or more years. This effect can be achieved in the setting of lower or comparable costs of treatment, which allows improved cost-effectiveness to be achieved when applying the prolgolimab + nurulimab combination.